Immune checkpoint inhibitors (ICIs) is a negative regulatory factor antibody, which activates T cells to play an anti-tumor effect in immunotherapy, and can also cause immune-related adverse responses, thereby inducing a series of immune related adverse events (irAEs). Among these irAEs, although the incidence of ICIs-related myocarditis is very low, the fatality rate is significantly higher than other adverse reactions, close to 50%. Clinicians should be vigilant when applying ICIs, but the pathogenesis of ICIs-related myocarditis is still unclear. This article combines the recent research results of ICIs to summarize the mechanism and clinical manifestations of ICIs-related myocarditis, so as to improve clinicians' understanding of the adverse reactions. .
【中文题目：免疫检查点抑制剂相关心肌炎的研究进展】 【中文摘要：免疫检查点抑制剂（immune checkpoint inhibitors, ICIs）是一种负性调节因子抗体，激活T细胞发挥免疫治疗抗肿瘤作用的同时，也可引起免疫相关的不良应答，从而诱导出一系列免疫相关不良反应（immune related adverse events, irAEs）。在这些irAEs中，ICIs相关心肌炎的发病率虽然很低，但致死率却明显高于其他不良反应，接近50%，临床医生应用ICIs时应提高警惕，但目前ICIs相关心肌炎的发病机制仍不明确。本文结合近期ICIs的研究成果对ICIs相关性心肌炎的发生机制及临床表现等方面作一综述，以提高临床医生对该不良反应的认识。 】 【中文关键词：免疫检查点抑制剂；心肌炎；心脏毒性】.
Keywords: Cardiotoxicity; Immune checkpoint inhibitor; Myocarditis.